GlassScriptPhysician profile
Lamont T Bunyon
NPI 1922141076
$4,961.07
in general payments reported to CMS, 2019-2025
17 companies · $640 in 2025
The $640 reported for 2025 was more than what 76% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $85.17 · 2021: $74.52 · 2022: $479 · 2023: $2,472 · 2024: $1,101 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,692 · Travel and Lodging: $1,301 · Entertainment: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.00 |
| Travel and Lodging | $1,301.33 |
| Entertainment | $219.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,753.61 | 2022-2023 | Visumax |
| Alcon Vision LLC | $634.80 | 2021-2024 | Total30, Precision 1 |
| Coopervision INC. | $494.14 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Lkc Technologies, INC. | $346.63 | 2023-2024 | |
| Sun Pharmaceutical Industries INC. | $276.95 | 2020-2024 | Cequa |
| Johnson & Johnson Vision Care, INC. | $232.35 | 2023 | Acuvue |
| Optos, INC. | $219.27 | 2023-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $181.56 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $153.12 | 2025 | Infuse |
| Oyster Point Pharma, INC. | $146.76 | 2022 | |
| Dompe US, INC. | $141.07 | 2021-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $109.54 | 2019 | |
| Heru, INC. | $90.32 | 2022 | |
| Sight Sciences, INC. | $64.31 | 2020 | |
| Biotissue Holdings INC. | $61.43 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $38.96 | 2021 | |
| Oasis Medical, INC. | $16.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamont Bunyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.